Device hybrid approval not the same as substance authorisation, rules CJEU
In a decision that will disappoint medical device manufacturers, the CJEU in the Boston Scientific case has addressed the authorisation that must form the basis of an SPC. This is in contrast to recent referrals that address what products can be protected
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
